Watch OCUL. Know when insiders buy.
One email the day a filing lands. Free.
Work order
35
FLAG · insiders 35, shorts 34
Insiders, 90 days
−$333K
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.3BP/E —DIV YIELD —FCF YIELD -10.92%REV TTM $52.1M −8.1%NET INCOME −$301.4MNET CASH $580.6M52W 6.88 – 16.11SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $13.5M | +0.1% | 85.1% | −$82.1M | −$78.8M | — | -0.35 | −$67.3M | $3.4M | −$70.6M | Aug 3 |
| Q1 2026 · Mar 31 | $10.8M | +0.8% | 87.7% | −$93.3M | −$88.6M | — | -0.40 | −$66M | $4.7M | −$70.7M | Aug 3 |
| Q4 2025 · Dec 31derived | $13.3M | −22.4% | 88.0% | −$69.8M | −$64.7M | — | -0.27 | −$54.2M | $2.8M | −$57.1M | Feb 5 |
| Q3 2025 · Sep 30 | $14.5M | −5.7% | 87.8% | −$68.7M | −$69.4M | — | -0.38 | −$50.7M | $6M | −$56.7M | Nov 4 |
| Q2 2025 · Jun 30 | $13.5M | −18.1% | 85.6% | −$67.6M | −$67.8M | — | -0.39 | −$55.2M | $1.2M | −$56.5M | Aug 3 |
| Q1 2025 · Mar 31 | $10.7M | −27.6% | 88.2% | −$63.9M | −$64.1M | — | -0.38 | −$44.7M | $1.9M | −$46.6M | Aug 3 |
| Q4 2024 · Dec 31derived | $17.1M | +15.4% | 92.8% | −$50.6M | −$48.4M | — | -0.28 | −$39.4M | $202K | −$39.6M | Feb 5 |
| Q3 2024 · Sep 30 | $15.4M | +2.3% | 89.9% | −$46M | −$36.5M | — | -0.22 | −$36.6M | $89K | −$36.6M | Nov 4 |
| Q2 2024 · Jun 30 | $16.4M | — | 90.8% | −$43.6M | −$43.8M | — | -0.26 | −$24.8M | $742K | −$25.5M | Nov 4 |
| Q1 2024 · Mar 31 | $14.8M | — | 91.0% | −$31.6M | −$64.8M | — | -0.49 | −$33.9M | $255K | −$34.1M | Nov 4 |
| Q4 2023 · Dec 31derived | $14.8M | — | 90.6% | −$20.1M | −$29.2M | — | -0.25 | −$22.5M | $459K | −$22.9M | Feb 5 |
| Q3 2023 · Sep 30 | $15.1M | — | 90.9% | −$19.2M | −$516K | — | -0.25 | −$7.7M | $259K | −$8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $52M | 87.3% | −$270M | −$265.9M | -511.9% | -1.42 | −$204.9M | $12M | −$216.9M | — | — |
| FY2024 · to Dec 31 | $63.7M | 91.2% | −$171.8M | −$193.5M | -303.7% | -1.22 | −$134.7M | $1.3M | −$136M | — | — |
| FY2023 · to Dec 31 | $58.4M | 91.0% | −$82.4M | −$80.7M | -138.1% | -1.02 | −$70.2M | $6.1M | −$76.3M | — | — |
| FY2022 · to Dec 31 | $51.5M | 91.2% | −$78.7M | −$71M | -138.0% | -0.97 | −$59.6M | $3.7M | −$63.3M | — | — |
| FY2021 · to Dec 31 | $43.5M | 89.9% | −$78M | −$6.6M | -15.1% | -0.98 | −$65.5M | $1.2M | −$66.7M | — | — |
| FY2020 · to Dec 31 | $17.4M | 88.0% | −$62.8M | −$155.6M | -894.3% | -2.56 | −$53.6M | $841K | −$54.4M | — | — |
Every number comes from OCULAR THERAPEUTIX, INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.